Advances Research of Sacubitril-valsartan's Pleiotropic Effects on Cardiovascular Diseases

Sacubitril-valsartan is the first-in-class angiotensin receptor-neprilysin inhibitor, with dual action mechanism that is antagonistic angiotensin Ⅱ receptor while inhibiting neprilysin. Datas from clinical studies of Sacubitril-valsartan suggest it has potential for the treatment of a variety of cardiovascular diseases. Familiar with the clinical application of Sacubitril-valsartan, has profound significance for the better development of it. According to the correlative reports in recent years, this paper reviewed it's pharmacologica mechanism and clinicalor animal trials of the heart failure with reduced ejection fraction and heart failure with preserved ejection fraction and other aspects such as hypertension, chronic renal impairment, and following myocardial infarction.